The basis of encapsulation is the design and development of the delivery system. A well-designed delivery system allows circRNA molecules to enter the body without being degraded by RNA enzymes and then be effectively delivered to the target site, cross the cell membrane, and be released intracellularly.
Lipid nanoparticles (LNPs) are the best delivery system available, with advantages in encapsulation, in vivo expression, and in vivo safety compared to other delivery systems. LNPs with nucleic acid fragments are easily swallowed into cells and form intracellular bodies. Once entering the cell, the acidic environment of the intracellular body protonates and positively charges the head of the ionized lipid, thus fusing with the inner membrane of the intracellular body and releasing the target nucleic acid into the cell for action.
Yaohai Bio-Pharma circRNA service continues to improve and can provide circRNA-LNP encapsulation service to optimize relevant critical process parameters and improve the consistency and reproducibility of circRNA drug production.
Services Details
| Process |
Service Details |
Delivery Period (Day) |
Deliverables |
| circRNA-LNP encapsulation |
Material and liquid pretreatment |
2 |
circRNA-LNP drug product (DP) |
| Microfluidic device mixing |
| Tangential flow filtration |
1 |
| Sterilizing filtration |
| circRNA-LNP quality control |
Encapsulation efficiency |
1 |
Test Report |
| Particle size and Polydispersity index |
| Zeta potential |
Our Features
- Formulation screening of drug product (DP)
Fast synthesis, high R&D efficiency and pre-optimized solutions;
- High encapsulation efficiency
The encapsulation ratio can reach more than 90%;
The size of lipid nanoparticles can be controlled by changing the fluid injection rate and ratio;
circRNA-LNP products are validated by in vitro cell expression and can express the target protein efficiently.
CaseStudy
LNP-eGFP circRNA samples are prepared and the different doses of them (1ug, 2ug, and 4ug) are directly transfected into 293T cells to verify whether they can express the target protein. After 48h of transfection, a clear fluorescent signal can be observed, and there is a dose-escalation effect of fluorescence intensity.
Lipo-circ_eGFP,made up of liposome and unencapsulated eGFP circRNA is taken as a control.
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
